Spiro-lactam NMDA Modulators for CNS Disorders

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for novel and more specific or potent compounds that can modulate NMDA receptors, particularly for pharmaceutical benefits, and a need for orally deliverable forms of such compounds to address various CNS disorders.

Innovation Solution

The development of compounds with Formula I, which include specific structural elements allowing for modulation of NMDA receptors, and their use in pharmaceutical compositions suitable for various administration routes, including oral administration, to treat a range of conditions including CNS disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing NMDA receptor modulators are used, then therapeutic benefits are achieved, but specificity and potency are insufficient

Engineering Contradiction:

Improvetherapeutic benefitVSAvoidspecificity and potency

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent introduces specific substituent groups (R1-R6) at different positions on the core chemical structure, allowing each position to be optimized independently for enhanced binding affinity and selectivity to NMDA receptors while maintaining overall therapeutic efficacy

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent systematically varies chemical parameters including substituent types, ring sizes (m=0,1,2 and n=1,2), and heteroatom composition (X=O or S) to optimize the balance between potency, specificity, and therapeutic index of the NMDA modulators

Inventive Principle:

Principle #35Parameter changes

2Reliability

If NMDA receptor modulators are administered, then therapeutic effects are achieved, but oral deliverability is limited

Engineering Contradiction:

Improvetherapeutic effectVSAvoidoral deliverability

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent modifies physicochemical parameters of the modulator molecules including molecular weight, lipophilicity, and functional group composition to improve oral absorption, bioavailability, and metabolic stability while preserving NMDA receptor binding activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates chemically composite structures combining the core NMDA-modulating pharmacophore with various substituent groups that collectively provide both high receptor affinity and improved pharmacokinetic properties for oral administration

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds effectively bind to NMDA receptors, providing therapeutic benefits for conditions such as depression, schizophrenia, and other CNS disorders, with potential for high therapeutic index and efficient delivery.

Implementation Method 1

The compounds effectively bind to NMDA receptors, providing therapeutic benefits for conditions such as depression, schizophrenia, and other CNS disorders

Methodology Applied

Scientific EffectMolecular binding:

Data Source

PatentUS20250002495A1Spiro-lactam NMDA modulators and methods of using same

Publication Date: 2025.01.02 TENACIA BIOTECHNOLOGY (HONG KONG) CO LTD

AI summary

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.